Supplementary Figure 8 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling | Synapse
March 11, 2024Open Access
Supplementary Figure 8 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Expression levels of genes of interest across human breast cancer cell lines